Aya Mohamed, Associate Lecturer of Medical Oncology, Member of ASCO, shared on X:
“FeDeriCa final analysis confirms that fixed-dose subcutaneous pertuzumab/trastuzumab delivers comparable long-term outcomes to IV therapy, with durable 4 yrs efficacy, reassuring cardiac safety, and no new safety signals.”
Title: Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer
Authors: C. Jackisch, S.-A. Im, A. Mattar, R. Colomer, D. Stroyakovskiy, Z. Nowecki, M. De Laurentiis, J.-Y. Pierga, K.H. Jung, C. Schem, S. Heeson, I. Yan, B. Wang, E. Restuccia, A.R. Tan.
Read the full article.
You might be interested in:
FeDeriCa: 4-Year Outcomes Support Subcutaneous HER2 Therapy
